Switzerland Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure medication, and the intricacies of market access in Switzerland. Could you please start by introducing Servier’s Swiss affiliate? We enjoy a longstanding presence and reputation in Switzerland. The local affiliate…
Pharma 2016 has been a great year for PharmaBoardroom, with interviews from global CEOs and ministers, groundbreaking country reports on some of the world’s key pharma markets, and insightful articles which get to the heart of the sector’s key issues. Stay tuned in 2017 for more of the same! INTERVIEWS OF…
Ireland Frederic Secail, General Manager of Servier’s second strategic and international production facility within Servier Industry, located in Arklow, Ireland, outlines his ambitious transformation program, Arklow 2020, to anticipate and prepare the site for the future. You have been GM of Servier’s Arklow facility since 2013. What was the mandate given…
France Shedding light on the unique business model of French pharma’s most successful mid-cap. Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier has, for…
Pharma Servier GM Florent Darchez, reveals how he turned around a Mexico affiliate that was losing market share to achieve and impressive sales growth of 30 percent a year. Darchez also shares his vision for further strengthening his organization. We see that in 2016, around 60 percent of Servier revenues derived…
Pharma The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute of Medicinal Chemistry (SRIMC) in Hungary plays in the group’s overall R&D activities. He also elaborates on the crucial importance…
Pharma Olivier Laureau, President of the Servier Group, discusses how Servier´s economic model is based on considerable investments in R&D to provide for a better future and on a strong international footprint; and how their ambition is to grow from total revenues of 4 billion euros (4.46 billion USD) today, to…
Pharma André Choulika, founder & CEO of Cellectis, reveals why the 21st century will be the century of gene editing and Cellectis will be one of the leaders of this revolution; how unlike many of their competitors, they are a gene editing company at the core and why the idea of…
Pharma Servier Egypt’s recently arrived general manager shares his first impressions and assessments of the Egyptian business environment, and discusses the potential he sees for Servier Egypt to build upon its already strong position in the market. After three months in Egypt, what is your initial assessment of the country? Upon…
Thailand Servier Thailand’s general manager discusses the company’s competitive role in Thailand despite market challenges, the company’s ability to remain innovative and successful regardless of Thailand’s changing policies and Servier’s unique work culture. Servier Thailand hopes to continue improving its service offerings in the local market by working closely with…
Servier Turkey is a key market in the region for Servier, says general manager Philippe Méa, largely due to the country’s relatively strong and stable vision for the healthcare industry. The success of single pill combinations will be a milestone for Servier’s business model. You arrived in Turkey eight months ago,…
Servier The general manager of Servier Morocco reviews the situation of the market following the recent price cuts, how the local environment is changing with the rise of generics, and reveals his vision of creating a regional hub for Servier in Morocco. Today, Servier is number one in the Moroccan market for…
See our Cookie Privacy Policy Here